Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 5, 2011, Pages 843-850

  El Awady, Mostafa K ^a   Anany, Mohamed A ^a   Esmat, Gamal ^b   Zayed, Naglaa ^b   Tabll, Ashraf A ^a   Helmy, Amr ^e   El Zayady, Abdel Rahman ^c   Abdalla, Mohga S ^f   Sharada, Hayat M ^f   El Raziky, Maissa ^b   El Akel, Wafaa ^b   Abdalla, Shadia ^d   Bader El Din, Noha G ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c Cairo Liver Center   (Egypt)

^d El Sahel Teaching Hospital   (Egypt)

^e National Liver Institute   (Egypt)

^f Helwan University   (Egypt)

Author keywords

Hepatitis C virus; Liver fibrosis; OAS1; Response to interferon therapy; Single nucleotide polymorphism

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ADENINE; BIOLOGICAL MARKER; DNA FRAGMENT; GUANINE; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DNA SPLICING; DRUG RESPONSE; EXON; FEMALE; GENE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATION RATE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79954496163     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06605.x     Document Type: Article

References (47)

1. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
2. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-82.
3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
4. Davis GL, Balart LA, Schiff ER. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1989; 321: 1501-6.
5. Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. N. Engl. J. Med. 1997; 336: 347-56.
6. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 1998; 95: 15623-8.
7. Tsubota A, Chayama K, Ikeda K etal. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
8. Gale M Jr., Foy EM. Evasion of intracellular host defense by hepatitis C virus. Nature 2005; 436: 939-45.
9. Ben-Ari Z, Mor E, Papo O etal. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am. J. Gastroenterol. 2003; 98: 144-52.
10. Hamano E, Hijikata M, Itoyama S etal. Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. Biochem. Biophys. Res. Commun. 2005; 329: 1234-42.
11. Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res. 2001; 52: 113-20.
12. Suh Y, Vijg J. SNP discovery in associating genetic variation with human disease phenotypes. Mutat. Res. 2005; 573: 41-50.
13. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 2001; 12: 143-56.
14. Sen GC. Viruses and interferons. Annu. Rev. Microbiol. 2001; 55: 255-81.
15. Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003; 42: 1805-12.
16. Xiang Y, Wang Z, Murakami J etal. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′-5′-oligoadenylates. Cancer Res. 2003; 63: 6795-801.
17. Justesen J, Hartmann R, Kjeldgaard NO. Structure and function of the 2′-5′-oligoadenylate synthetase family. Cell. Mol. Life Sci. 2000; 57: 1593-612.
18. Mashimo T, Lucas M, Simon-Chazottes D etal. A nonsense mutation in the gene encoding 2--5--oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc. Natl. Acad. Sci. USA 2002; 99: 11311-16.
19. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. Positional cloning of the murine flavivirus resistance gene. Proc. Natl. Acad. Sci. USA 2002; 99: 9322-7.
20. Lucas M, Mashimo T, Frenkiel MP etal. Infection of mouse neurones by West Nile virus is modulated by the interferon-inducible 2′-5′-oligoadenylate synthetase 1b protein. Immunol. Cell Biol. 2003; 81: 230-6.
21. Bonnevie-Nielsen V, Martensen PM, Justesen J etal. The antiviral defense system is persistently activated in human type 1 diabetes. Clin. Immunol. 2000; 96: 11-18.
22. Bonnevie-Nielsen V, Larsen ML, Frifelt JJ, Michelsen B, Lernmark A. Association of IDDM and attenuated response of 2′-5′-oligoadenylate synthetase to yellow fever vaccine. Diabetes 1989; 38: 1636-42.
23. Naganuma A, Nozaki A, Tanaka T etal. Activation of the interferon-inducible 2′-5′-oligoadenylate synthetase gene by hepatitis C virus core protein. J. Virol. 2000; 74: 8744-50.
24. Karino Y, Hige S, Saga A etal. Relationship Between Serum 20-50 Oligoadenylate Synthase Activity and the Reduction of HCV-RNA During Interferon Therapy. Tokyo: Springer, 1994; 631-4.
25. Bonnevie-Nielsen V, Field L, Lu S etal. Variation in antiviral 2′-5′-oligoadenylate synthetase (2′-5′-AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am. J. Hum. Genet. 2005; 76: 623-33.
26. Ghosh A, Sarkar SN, Rowe TM, Sen GC. A specific isozyme of 2′-5′-oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J. Biol. Chem. 2001; 276: 25447-55.
27. King JK, Yeh SH, Lin MW etal. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: a pilot study. Hepatology 2002; 36: 1416-30.
28. Suzuki F, Arase Y, Suzuki Y etal. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral Hepat. 2004; 11: 271-80.
29. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
30. El Awady M, Badr El Din N, El Garf W etal. Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells. Cancer Cell Int. 2006; 6: 18-27.
31. El Awady M, Tabll A, El-Abd Y etal. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. World J. Gastroenterol. 2006; 12: 4836-42.
32. Thakeb F, El-Serafy M, Zakaria S etal. Evaluation of liver tissue by polymerase chain reaction for hepatitis B virus in patients with negative viremia. World J. Gastroenterol. 2005; 11: 6853-7.
33. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005; 5: 558-67.
34. Omran MH, Youssef S, El-Garf W etal. Phylogenetic and genotyping of hepatitis C virus in Egypt. Aust. J. Basic Appl. Sci. 2009; 3 (1): 1-8.
35. Matsushita M, Hijikata M, Matsushita M, Ohta Y, Mishiro S. Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J. Hepatol. 1998; 29: 695-700.
36. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon1. Intervirology 2000; 43: 124-7.
37. Knapp S, Yee S, Frodsham AJ etal. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003; 4: 411-19.
38. Mashimo T, Simon-Chazottes D, Guénet JL. Innate resistance to flavivirus infections and the functions of 2′-5′-oligoadenylate synthetases. Curr. Top. Microbiol. Immunol. 2008; 321: 85-100.
39. Lim JK, Lisco A, McDermott DH etal. Genetic variation in OAS1 is a risk factor for initial infection with West Nile Virus in man. PLoS Pathog. 2009; 5: e1000321.
40. Li C, Kato N, Chang J etal. Polymorphism of OAS-1determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver Int. 2009; 29: 1413-21.
41. Okuno T, Shindo M, Arai K etal. Determination of 2′, 5′ Oligoadenylate Synthetase Acitvity in Acute Non-A, Non-B Hepatitis Patients, with Special Reference of Histological Outcome. Viral Hepatitis C, D and E. Amsterdam: Elsevier, 1991; 133-5.
42. Solinas A, Cossu P, Poddighe P etal. Changes of serum 2′, 5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. Liver 1993; 13: 253-8.
43. Pawlotsky JM, Hovanessian A, Roudot-Thoraval F etal. Activity of the interferon-induced 20, 50-oligoadenylate synthetase in patients with chronic hepatitis C. J. Interferon Cytokine Res. 1995; 15: 857-62.
44. Peng XM, Lei RX, Gu L, Ma HH, Xie QF, Gao ZL. Influences of MxA gene -88 G/T and IFN-gamma +874 A/T on the natural history of hepatitis B virus infection in an endemic area. Int. J. Immunogenet. 2007; 34: 341-6.
45. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
46. Chevaliez S, Hézode C. IL28B polymorphisms and chronic hepatitis C. Gastroenterol. Clin. Biol. 2010; 34: 587-9.
47. Bader El Din NG, Meguid MA, Tabll AA etal. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. J. Gastroenterol. Hepatol. 2011; 26: 55-62. (in press).